Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asciminib in Indian Patients With Ph+ CML-CP
NCT06427811Phase 4Completed
- Sponsor
- Novartis
- Start
- Nov 2024
- Primary completion
- Mar 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of asciminib in chronic myeloid leukemia (CML), sponsored by Novartis. Primary endpoint: Frequency and severity of adverse events and serious adverse events at 6 months. Started Nov 2024; status: completed.
02
Drugs
asciminib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT06427811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06427811.